Allogene Therapeutics
Saurav Mahanti is an accomplished executive in Information Technology with extensive experience across various companies. Currently serving as the Executive Director of Information Technology at Allogene Therapeutics since February 2020, Saurav leads a comprehensive Data and Analytics Strategy, facilitating valuable insights for scientific and business inquiries. Prior to this role, Saurav held positions at Facebook as Data Engineering Lead, focusing on elections integrity, and at Amgen, where responsibilities included directing data management and analytics for process development, implementing Big Data strategies, and supporting enterprise data warehousing efforts. Saurav's earlier career included consulting roles at Wipro Technologies and TCS, contributing to data warehousing and system analysis projects. Saurav holds a Bachelor of Engineering in Electronics and Telecommunications from the University College of Engineering, Burla.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.